Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - CEPT inhibition - all type of patients

cardiovascular prevention - HDL increasing drugs - all type of patients

Related trials

ACCELERATE, 2015 - evacetrapib vs placebo

dal-OUTCOMES, 2012 - dalcetrapib vs placebo

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

dal-VESSEL, 2011 - dalcetrapib vs placebo

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

DEFINE, 2010 - anacetrapib vs placebo

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

ARBITER 2, 2009 - niacin vs placebo (on top statin)

ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

RADIANCE 1, 2007 - torcetrapib vs placebo (on top of atorvastatin)

ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)

FIELD, 2005 - fenofibrate vs placebo

LEADER, 2002 - bezafibrate vs placebo

DAIS, 2001 - fenofibrate vs placebo

HATS, 2001 - niacin vs placebo (on top statin)

BIP, 2000 - bezafibrate vs placebo

VA-HIT, 1999 - gemfibrozil vs placebo

SENDCAP, 1998 - bezafibrate vs placebo

LOCAT, 1997 - gemfibrozil vs placebo

BECAIT, 1996 - bezafibrate vs placebo

HHS (Frick)(secondary prev subgroup), 1993 - gemfibrozil vs placebo

Hanefeld, 1991 - clofibrate vs placebo

See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of HDL increasing drugs
  • All clinical trials of torcetrapib
     RADIANCE 2 study, 2007 TRC9363 
    download pdf: torcetrapib | CEPT inhibition for cardiovascular prevention


    Studied treatment torcetrapib 60mg daily (on top of atorvastatin attitrated dose)
    Control treatment placebo +atorvastatin attitrated dose


    Patients patients with mixed dyslipidaemia
    Inclusion criteria triglycerides of greater than 1�7 mmol/L; LDL cholesterol concentration high enough to qualify for statin treatment according to NCEP Adult Treatment Panel

    Method and design

    Randomized effectives 377 / 375 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 24 months
    Number of centre 64
    Geographic area North America and Europe
    Primary endpoint maximum intima-media thickness of 12 carotid segments


    No results available for this trial - no clinical endpoint reported

    Meta-analysis of all similar trials:

    CEPT inhibition in cardiovascular prevention for all type of patients

    HDL increasing drugs in cardiovascular prevention for all type of patients


    TrialResults-center ID TRC9363
    Trials register # NA
    • Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.. Lancet 2007;370:153-60
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels